|
|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2026
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/34415
| Title: | GENETICALLY CONFIRMED AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE TYPE 1 (PKD1) |
| Authors: | Gutu, Biatricia Sasu, Boris Groppa, Liliana Ceban, Emil |
| Keywords: | ADPKD;PKD1;genetic;family screening |
| Issue Date: | 2026 |
| Publisher: | Centrul Editorial-Poligrafic Medicina |
| Citation: | Gutu, Biatricia; Sasu, Boris; Groppa, Liliana; Ceban, Emil. GENETICALLY CONFIRMED AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE TYPE 1 (PKD1). In: MedEspera 2026, p. 600. ISBN 978-9975-82-486-6. |
| Abstract: | Introduction. Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and accounts for approximately 5-10% of cases of end-stage kidney disease worldwide. Mutations in the PKD1 gene are associated with a more severe phenotype and faster disease progression compared with PKD2 variants. Molecular diagnosis and systematic family screening play an important role in identifying affected individuals at early stages and enabling appropriate clinical monitoring. Case presentation. We report the case of a 31-year-old female with a family history consistent with ADPKD. Her father progressed to end-stage kidney disease and underwent kidney transplantation at the age of 50, while her sister was diagnosed with ADPKD at the age of 12. The disease was detected in the patient at the age of 25 during family screening. She presented with intermittent bilateral lumbar pain, dysuria, and occasional episodes of hematuria. Since 2019, the patient has been receiving ACE inhibitor therapy for nephroprotection. Laboratory tests showed preserved kidney function, with serum creatinine of 61.8 pmol/L and an estimated glomerular filtration rate >90 ml/min/1.73 m2, corresponding to CKD stage G1 according to KDIGO classification. Hematological parameters and inflammatory markers were within normal limits. Dyslipidemia was identified, with total cholesterol of 5.74 mmol/L, LDL cholesterol 3.99 mmol/L, and triglycerides 3.61 mmol/L. Abdominal magnetic resonance imaging revealed bilaterally enlarged kidneys with multiple diffusely distributed intraparenchymal cysts. The maximal longitudinal renal diameter measured 12.4 cm for the right kidney and 17.0 cm for the left kidney. The largest cysts measured 32^43 mm in the right kidney and 57x48 mm in the lower pole of the left kidney. Extrarenal findings included hepatomegaly associated with diffuse hepatic steatosis. Discussions. Genetic testing performed in a specialized center in Iaşi identified a heterozygous pathogenic variant in the PKD1 gene (c.2702G>A, p.Trp901*), classified by ACMG criteria as a class V pathogenic variant. This nonsense mutation introduces a premature stop codon, causing truncation of the polycystin-1 protein and loss of function, a mechanism associated with a more severe ADPKD phenotype and faster disease progression. Molecular confirmation is particularly important in patients detected through family screening, enabling early diagnosis, improved prognostic stratification, and appropriate clinical follow-up. Conclusions. This case highlights the importance of family screening and molecular genetic testing for early identification of ADPKD, even with preserved kidney function. Integration of imaging and genetic data enables accurate diagnosis, prognostic assessment, and appropriate monitoring to slow disease progression and reduce cardiovascular risk. |
| metadata.dc.relation.ispartof: | MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026 |
| URI: | https://medespera.md/documents/abstract-book-4.pdf https://repository.usmf.md/handle/20.500.12710/34415 |
| ISBN: | 978-9975-82-486-6 |
| Appears in Collections: | MedEspera 2026
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|